Navigation Links
Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU
Date:7/16/2008

for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the continued development and commercialization of Kuvan and BioMarin's other products and product candidates and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Kuvan; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2007 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 10-Q and Form 8-K. Stockholders are urged not to
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
2. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
3. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
4. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
5. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
6. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
7. Clexane(R)/Lovenox(R) Approved in Japan
8. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
9. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
10. Lucids VivaScope(R) Reflective Confocal Microscope Approved for Sale in China
11. Naglazyme Approved by Japanese Ministry of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 regulated information -- UCB ... and development pipeline with positive topline results from ... . This study was designed to evaluate the efficacy ... 200 mg/day, without titration) compared to placebo, as ... partial-onset seizures, not fully controlled despite treatment with ...
(Date:7/23/2014)... , July 23, 2014 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... Limited ("Cordlife"), a multi-product healthcare company catering to the mother and ... in assisting patients across the PRC, Singapore , ... India , the Philippines ...
(Date:7/23/2014)... July 23, 2014 Adult stem ... therapies are biological, but not magical. However, ... to treat them as if they were magical. ... unsanctioned studies that constitute “stem cell tourism,” are ... approach to developing new regenerative medicine therapies. In ...
(Date:7/22/2014)... a phylum so full of mean little creatures, the yellow-colored ... cruelty -- at least to crickets. Native to the southeastern ... predatory sort of parasite. It swoops onto the back of ... leaves its wicked brood to invade, kill and consume the ... be possible without the fly,s ability to find a cricket ...
Breaking Biology Technology:Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4
... Md., Aug. 14 Martek Biosciences,Corporation announced that it ... fiscal 2007 on September 5, 2007, at approximately 4:00 ... p.m. EDT Martek,will hold a conference call to discuss ... investors. The call is expected to be approximately one,hour ...
... 14 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc.,(TSX: DDD; OTCBB: DRUG; BBSE: DRP) ... 2007. Highlights of the Second Quarter, 2007, - ... the same period of 2006, and ... quarter 2007;, - Gross profit and gross ...
... 15 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: ... oncology company that identifies,develops and commercializes differentiated ... AG (Wedel, Germany), its European partner,for the ... has recruited the 40th and final patient ...
Cached Biology Technology:Martek to Announce Third Quarter 2007 Results on September 5, 2007 2Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007 2Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007 3ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB 2ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB 3ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB 4
(Date:7/22/2014)... UT Arlington computer science and engineering professor with an ... three-year National Science Foundation grant worth more than $600,000 ... the fruit fly., Heng Huang, an associate professor, will ... the UT Arlington Computer Science and Engineering department. Scientists ... because a large number of genes involved in fruit ...
(Date:7/22/2014)... be good for the average steak, but it seems ... to survive Alaska,s winter cold. , "Alaska wood frogs ... steak does in your freezer and the frog comes ... than the steak," said Don Larson, University of Alaska ... paper demonstrating that freeze tolerance in Alaska wood frogs ...
(Date:7/22/2014)... Researchers from the USC Schaeffer Center for Health ... governing antipsychotic drugs with increased incarceration rates for ... scrutiny over whether cutbacks in mental health actually ... account. , Some health plans require an extra ... ordered for patients. This step called prior ...
Breaking Biology News(10 mins):UT Arlington big data team wins $600,000 NSF grant to build gene expression database 2Alaska frogs reach record lows in extreme temperature survival 2Alaska frogs reach record lows in extreme temperature survival 3Are state Medicaid policies sentencing people with mental illnesses to prison? 2
... F. Harrington Professor Emeritus at the University of Delaware, ... Heck, 79, was honored alongside fellow researchers Akira Suzuki, ... Negishi, 75, of Purdue University, "for palladium-catalyzed cross couplings ... award. The Nobel Prize in Chemistry was announced ...
... National Science Foundation (NSF) grant to upgrade and expand ... Solar Array (OVSA) http://www.ovsa.njit.edu/ has been ... to help scientists better understand the nature of solar ... "Space weather incidents such as coronal mass ...
... State University finds that fish located near coal-fired power plants ... further away. The surprising finding appears to be linked to ... which unfortunately poses problems of its own. "We found ... from a coal-fired power plant had mercury levels more than ...
Cached Biology News:UD Professor Emeritus wins Nobel Prize in Chemistry 2$5 million NSF grant will upgrade and expand NJIT radio telescope array 2$5 million NSF grant will upgrade and expand NJIT radio telescope array 3Study: Fish near coal-fired power plants have lower levels of mercury 2
... Recognizes Nabeta2. The epitope ... present in any other known ... expected to work on human ... highly conserved (17/19 residues). Reactivity ...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
... for DNA isolation. Designed to ... 96 well plate adapters from Mo ... entire plate length (max capacity is ... used for soil, microorganisms, animal tissue, ...
Biology Products: